Alternative splicing of synuclein gamma in endometrial cancer: identification of a novel isoform
Metrics: PDF 656 views | HTML 920 views | ?
Kathrin Schaal1,2, Marc Hirschfeld1,3,4, Peter Bronsert3,4,5,6, Hannah Füllgraf5,6, Markus Jäger1, Bettina Herde5, Claudia Nöthling1, Sebastian Mayer1, Thalia Erbes1, Elmar Stickeler1,3,4,6
1Department of Obstetrics and Gynecology, University Medical Center, Freiburg, Germany
2Department of Urology, University Medical Center, Freiburg, Germany
3German Cancer Consortium (DKTK), Freiburg, Germany
4German Cancer Research Center (DKZF), Heidelberg, Germany
5Institute of Surgical Pathology, University Medical Center, Freiburg, Germany
6Comprehensive Cancer Center, University Medical Center, Freiburg, Germany
Elmar Stickeler, e-mail: firstname.lastname@example.org
Keywords: synuclein gamma, SNCG, alternative splicing, endometrial cancer, biomarker
Received: February 10, 2015 Accepted: May 23, 2015 Published: June 05, 2015
Synuclein gamma (SNCG) is under consideration as a potential biomarker in cancer biology. Up to date four different SNCG variants are described. Due to growing evidence suggesting correlations between aberrant alternative splicing processes and cancer progression, we investigated the effects of peritumoural conditions on expression pattern of SNCG in endometrial cancer (EC) in vitro. Compared to breast cancer cell lines, mRNA expression levels of all known SNCG isoforms 1–4 are significantly reduced in EC cell lines. We identified a novel alternatively spliced variant of isoform 2 (isoform 2 short) which is found highly expressed in EC cell lines. Hypoxia and acidosis trigger an up-regulation of isoform 2 short. EC cell lines are characterized by low SNCG protein levels under control conditions, but exhibit a significant increase triggered by hypoxia and acidosis. In addition we analysed the potential association between SNCG protein expression and clinico-pathological parameters in human EC samples. Our findings indicate a grade-dependent induction of SNCG protein expression in endometrial cancer.
We identified for the first time a novel isoform of SNCG that is found specifically expressed in EC. Our results also strongly indicate the existence of a corresponding protein of isoform 2 short that potentially plays a critical role in EC cancer progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.